Corvus Pharmaceuticals Bolsters Board with Novo Nordisk Veteran David Moore
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) has appointed David Moore to its Board of Directors, bolstering its strategic capabilities. Moore brings a wealth of experience from his roles at companies like Novo Nordisk and Pfizer.
Moore, who currently serves as Executive Vice President, US Operations at Novo Nordisk A/S and President at Novo Nordisk Inc., will provide valuable insights to Corvus. His 27-year industry experience spans strategy, commercial operations, market access, business development, and investing. At Novo Nordisk, he oversaw successful GLP-1 franchises like Ozempic, Wegovy, and Rybelsus.
Corvus, a clinical-stage biopharmaceutical company, focuses on ITK inhibition for cancer and immune diseases. Its lead product candidate, soquelitinib, is an investigational, oral, small molecule drug that selectively inhibits ITK. The company believes Moore's expertise will help maximize the potential of its ITK inhibitor platform. Corvus' other clinical-stage candidates are being developed for various cancer indications.
David Moore's appointment to Corvus Pharmaceuticals' board is expected to strengthen the company's strategic direction. His extensive experience in the industry, particularly in commercial operations and strategy, will be invaluable as Corvus continues to develop its ITK inhibitor platform and other cancer therapies. Investor inquiries can be directed to Leiv Lea, Chief Financial Officer, at 1-650-900-4522 or [email protected].